Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
Authors
Kyriakos P Papadopoulos
South Texas Accelerated Research Therapeutics (START), San Antonio, TX
Kyriakos P Papadopoulos, Taofeek Kunle Owonikoko, Melissa Johnson, Irene Brana, Marta Gil Martin, Raymond P. Perez, Victor Moreno, April K. Salama, Emiliano Calvo, Nelson S Yee, Howard Safran, Antonio Gonzalez Martin, Raid Aljumaily, Daruka Mahadevan, Kosalai Kal Mohan, Jingjin Li, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Jade Homsi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02383212
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 195)
DOI
10.1200/JCO.2018.36.5_suppl.195
Abstract #
195
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
First Author: Taofeek Kunle Owonikoko
First Author: Igor Tsaur
Poster
2023 ASCO Gastrointestinal Cancers Symposium
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
First Author: Miaozhen Qiu
Poster
2022 ASCO Annual Meeting
Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.
First Author: Xue Bai